Children on dialysis who have anemia and require high doses of drugs to treat it are at increased risk of dying prematurely.
Soluble ferric pyrophosphate significantly decreased ESA use while maintaining target hemoglobin levels without increasing iron stores.
The trend is most pronounced among Medicare recipients since the debut of bundling, ESA labeling changes.
Study also showed an increase in the proportion of patients with hemoglobin level below 10 g/dL and in transfusion rates.
Voluntary recall of anemia drug due to reports of anaphylaxis, including three deaths
Preoperative anemia associated with elevated risk of deaths from other illnesses.
Once-monthly injections of peginesatide are as effective as one to three injections per week of epoetin in maintaining hemoglobin levels.
No major adverse events reported with administering 1.02 grams of ferumoxytol in patients with iron deficiency anemia.
Meta-analysis also reveals an increased risk of vascular access thrombosis, but no increased likelihood of end-stage renal disease.
Hematocrit decreases as estimated glomerular filtration rate (eGFR) declines in hypertensive chronic kidney disease (CKD) patients.
Patients initiating daily hemodialysis (DHD) face a significant decrease in mean hemoglobin (Hb), hematocrit, and transferrin.
Intravenous ascorbic acid (IVAA) can be a potent and effective adjuvant treatment for hemodialysis patients who have normoferritinemic anemia resistant to treatment with erythropoietin (EPO).
Epoetin use and hemoglobin (Hb) levels have declined similarly for black and non-black dialysis patients following the advent of Medicare's system of "bundled" payments.
Iron deficiency in the absence of anemia is associated with intradialytic hypotension (IDH), a finding that suggests iron has a role beyond erythropoiesis.
Clinicians are prescribing less erythropoietin and more intravenous iron for anemic hemodialysis patients after the introduction of a prospective payment system (PPS) for dialysis services ("bundling") and changes to ESA drug labels.
Variant hemoglobin (Hb) is common in African-American hemodialysis patients and it is associated with a need for significantly increased doses of ESA.
Dosing intravenous (IV) iron at higher TSAT levels has only a modest effect on raising transferrin saturation (TSAT), ferritin, and hemoglobin in anemic hemodialysis patients.
Bolus dosing of intravenous (IV) iron is associated with an elevated risk of infection-related hospitalization among anemic hemodialysis (HD) patients compared with maintenance dosing.
NATIONAL HARBOR, Md.—Black hemodialysis (HD) patients with anemia require relatively more epoetin than their non-black counterparts to achieve similar hemoglobin (Hb) levels, but blacks and non-blacks required similar peginesatide doses, according to findings presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
NATIONAL HARBOR, Md.—Rapid anemia management (RAM) for patients with end-stage renal disease within seven days of hospital discharge decreases their rate of readmission, according to findings presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
Completely correcting anemia in kidney transplant recipients may preserve kidney function better than partially correcting anemia.
When using ESAs to correct anemia in patients with chronic kidney disease, focus less on hitting a given hemoglobin target.
The FDA has approved peginesatide (Omontys) for the treatment of anemia in adult dialysis patients.
Complete correction of anemia (hemoglobin, 13 g/dL or higher) in kidney transplant recipients slows progression to chronic allograft nephropathy, a study found.
The FDA's Oncologic Drugs Advisory Committee, in a 15 to 1 vote, has agreed that peginesatide demonstrates a favorable benefit/risk profile for use in treatment of dialysis patients with anemia resulting from chronic kidney disease (CKD).
PHILADELPHIA—A novel treatment for chronic kidney disease (CKD) patients with anemia is showing positive results following a Phase 1/2 clinical trial, according to findings reported at Kidney Week 2011.
Mortality in hemodialysis (HD) patients can be influenced by their responsiveness to erythropoiesis-stimulating agents (ESAs), according to Japanese researchers.
The FDA has agreed to review a New Drug Application (NDA) for peginesatide for the treatment of anemia associated with chronic kidney disease (CKD) in adult dialysis patients, according to a joint announcement by the two companies colloraborating on the development of the drug.
The FDA is calling for more conservative dosing of erythropoiesis-stimulating agents (ESAs) when used to treat anemia in CKD patients due to the increased risks of cardiovascular events such as stroke, thrombosis, and death.
The FDA is reviewing a New Drug Application for peginesatide as a treatment for anemia associated with chronic renal failure in adult dialysis patients.